Clinical trial NCT01234337: Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Official title: A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Breast Cancer
Keywords: Breast Cancer
HER2-neu
Lead sponsor: Bayer
Sponsor class: INDUSTRY
Collaborators: name: Onyx Therapeutics, Inc.
First posted: 2010-11-04
Enrollment: 537
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or metastatic HER2-negative breast cancer who are resistant to or have failed prior taxane and an anthracycline or for whom further anthracycline therapy is not indicated. After signing consent there can be up to 28 days before starting the treatment during which time a number of tests will be carried out which will include tumor evaluations and medical history. The following tests and evaluations will have to be done within 7 days of the start of treatment,on Day 1 of every cycle and at the end of study: Electrocardiogram, blood tests, patient quality of life questionnaires and a complete physical exam and vital signs. Treatment will be given in 21 day cycles with sorafenib/placebo to be taken every day for 21 days and capecitabine to be taken for the first 14 days. Patients will come in weekly for the first 6 weeks and then on Day1 for every cycle after the first 2 cycles. During the weekly visits the subjects will be check for any side effects and blood draws will happen for the study on Day 1 of each cycle. Subjects will be followed for overall survival.

Detailed description: Research summary (NRES, UK):

Breast cancer is the most commonly diagnosed cancer in women and the leading cause of cancer-related death among women worldwide.

However, despite advances in treatment of the early-stage disease, about 25-40% of patients will develop recurrence or spread to other parts of the body that is largely incurable. The average survival of patients with breast cancer that has spread to other parts of the body (metastasis) is 2 to 3 years after diagnosis, and although a number of treatment options are available, including various chemotherapy agents, no single standard of care exists.

The study drug (Sorafenib) works by inhibiting certain pathways in the body that contribute to tumour growth and the formation of new blood vessels (angiogenesis). Angiogenesis plays an important role in the development, transformation and spread of breast cancer. Capecitabine is an approved chemotherapy drug for patients whose breast cancer has spread to other parts of the body (metastatic) and is not responsive to other classes of chemotherapy drugs.

Data from a Phase IIb clinical study suggests that there is a role for the combination of Sorafenib and Capecitabine to treat locally advanced or metastatic breast cancer.

Patients in this confirmatory Phase III study will be randomly assigned to receive either:

* Capecitabine + Sorafenib
* Capecitabine + placebo ("dummy medication" with no active drug)

Participants will continue to receive treatments until there is radiographic or clinical progression of disease, side effects which require them to withdraw, pregnancy, protocol non-compliance or withdrawal of consent. Therefore length of participation will vary for individuals. This study is expected to close 31 March 2013.

This is a multicentre study which will take place across Europe, North and South America, Asia, Australia and South Africa. It is anticipated that approximately 519 participants will be recruited worldwide.

Eligibility criteria: Inclusion Criteria:

* Age is \>=18 years
* Subject has histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast. HER2 status should be determined by an accredited laboratory
* Subject has locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent. Must have measurable or non-measurable disease (according to RECIST \[Response Evaluation Criteria for Solid Tumors\] 1.1)
* All computer tomography (CT; with contrast) and magnetic resonance imaging (MRI) used to document disease must have been done \<= 4 weeks before randomization. Bone scans (if clinically indicated) must have been done \<= 12 weeks prior to randomization
* Subject must have received up to two prior chemotherapy regimens (adjuvant/neo-adjuvant treatments are considered one regimen), and no more than one prior regimen for advanced and/or metastatic disease. Chemotherapy regimens include both targeted and biologic therapy
* Prior regimens must have included an anthracycline (eg, doxorubicin, epirubicin) and a taxane (eg, paclitaxel, docetaxel), either in combination or in separate regimens, in either the neo-adjuvant/adjuvant or the metastatic setting or both, as either monotherapy or as part of a combination with another agent. Sequential regimens will count as a single regimen; multiple neo-adjuvant / adjuvant regimens will count as a single regimen
* Subjects are either resistant to or have failed prior taxane and anthracycline OR Resistant to or have failed prior taxane AND for whom further anthracycline therapy is not indicated (for example, intolerance or cumulative doses of doxorubicin or doxorubicin equivalents \[for example, epirubicin)
* Subjects who relapse beyond 12 months after the last taxane or anthracycline dose given in the adjuvant, neo-adjuvant, or metastatic setting are eligible. Further therapy with the agent(s) for a subsequent regimen must have been considered and ruled out, for example due to prior toxicity or intolerance, or based on the local standard of practice
* Prior experimental chemotherapy treatment is allowed, provided it is given in combination with at least one drug approved for the treatment of breast cancer (excluding drugs that target VEGF \[Vascular Endothelial Growth Factor\] or VEGFR \[Vascular Endothelial Growth Factor Receptor\], eg, bevacizumab, brivanib, sunitinib, vatalinib).
* Prior hormonal therapy for locally advanced or metastatic breast cancer is allowed. Subjects who are refractory to hormonal therapy are allowed.
* Prior neo-adjuvant or adjuvant chemotherapy is allowed.
* Subject must have discontinued prior chemotherapy (including both targeted and biologic therapies), prior therapeutic radiation therapy, or prior hormonal therapy for locally advanced or metastatic disease \>= 4 weeks (28 days) before randomization. Start of study treatment is allowed within less than 28 days of the prior therapy provided that 5 half-lives of the prior treatment drug(s) have elapsed
* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1
* Adequate bone marrow, liver and renal function within 7 days prior to randomization
* All acute toxic effects of any prior treatment have resolved to NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events) v4.0 Grade 1 or less
* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization
* Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF (Informed Consent Form) until at least 30 days after the last dose of study drug.
* Subject must be able to swallow and retain oral medication

Exclusion Criteria:

* HER2 positive breast cancer
* Unknown hormone receptor status (estrogen and progesterone receptor).
* Subjects with bilateral breast cancer or a history of two distinct breast cancers.
* Subjects with inflammatory breast carcinoma.
* Subjects who have received no prior taxane and anthracycline for the treatment of breast cancer (either in adjuvant, neo-adjuvant or metastatic setting).
* Prior use of sorafenib or capecitabine
* Subjects considered by the treating investigator to be appropriate candidates for hormonal therapy as current treatment for locally advanced/metastatic breast cancer
* Subjects with locally advanced disease who are considered by the treating investigator to be appropriate candidates for radiation therapy as current treatment for locally advanced breast cancer
* Subjects with active brain metastases or leptomeningeal disease.
* Subjects with seizure disorder requiring medication.
* Radiation to any lesions \<= 4 weeks prior to randomization. Palliative radiation to bone metastasis for pain control is permitted with provisions
* Major surgery, open biopsy, or significant traumatic injury \<= 4 weeks
* Evidence or history of bleeding diathesis or coagulopathy. Uncontrolled hypertension, active or clinically significant cardiac disease. Subject with thrombotic, embolic, venus or arterial events
* Subjects with any hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 3 or higher within 4 weeks before randomization
* Subjects with an infection of NCI-CTCAE v4.0 \> Grade 2
* Subjects with a history of human immunodeficiency virus infection or current chronic or active hepatitis B or C infection.
* Subjects who have used strong CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort \[Hypericum perforatum\], dexamethasone at a dose of greater than 16 mg daily, or rifampin \[rifampicin\], and/or rifabutin) within 28 days before randomization.
* Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer
* Subjects with a history DHPD (Dihydropyrimidine dehydrogenase) reaction to fluropyrimidine or history of known or suspected allergy or hypersensitivity to any of the study drugs
* Presence of a non-healing wound, non-healing ulcer, or bone fracture
* Women pregnant or breast feeding
* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation

Primary outcomes:
measure: Progression-free Survival (PFS) Assessed by the Independent Review Panel According to Response Evaluation Criteria for Solid Tumors (RECIST) 1.1
timeFrame: From randomization of the first participant until approximately 3 years or until disease radiological progression
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: From randomization of the first participant until approximately 3 years later
measure: Time to Progression (TTP) by Central Review
timeFrame: From randomization of the first participant until approximately 3 years later or until disease radiological progression
measure: Objective Response Rate (ORR) by Central Review
timeFrame: From randomization of the first participant until approximately 3 years later or until disease radiological progression
measure: Disease Control Rate (DCR) by Central Review
timeFrame: From randomization of the first participant until approximately 3 years later or until disease radiological progression
measure: Duration of Response (DOR) by Central Reader
timeFrame: From randomization of the first participant until approximately 3 years later or until disease radiological progression
Other outcomes:
measure: Patient Reported Outcomes: Functional Assessment of Cancer Therapy-Breast Symptom Index (8 Item) (FBSI-8)
timeFrame: Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, 31, 34, 37, and end of treatment (EOT, 21 days after last dose of study drug)
measure: Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Index Score
timeFrame: Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, and EOT (21 days after last dose of study drug)
measure: Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Visual Analogue Scale (VAS) Score
timeFrame: Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, and EOT (21 days after last dose of study drug)
measure: Maximum Observed Drug Concentration (Cmax) of Capecitabine and 5-fluorouracil
timeFrame: Pre-dose and 0.5, 1, 2, and 4 hours after capecitabine dosing at Cycle 2, Day 14
measure: Area Under Curve From Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Capecitabine and 5-fluorouracil
timeFrame: Pre-dose and 0.5, 1, 2, and 4 hours after capecitabine dosing at Cycle 2, Day 14
measure: Number of Participants With Treatment-emergent Grade 3 and 4 Laboratory Abnormalities
timeFrame: From the start of study treatment up to 30 days after the last dose
Locations:
city: Greenbrae
country: United States
state: California
city: Sylmar
country: United States
state: California
city: West Palm Beach
country: United States
state: Florida
city: Joliet
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: Louisville
country: United States
state: Kentucky
city: Boston
country: United States
state: Massachusetts
city: Boston
country: United States
state: Massachusetts
city: Jackson
country: United States
state: Mississippi
city: Springfield
country: United States
state: Missouri
city: Albuquerque
country: United States
state: New Mexico
city: Lake Success
country: United States
state: New York
city: Durham
country: United States
state: North Carolina
city: Philadelphia
country: United States
state: Pennsylvania
city: Bristol
country: United States
state: Tennessee
city: Memphis
country: United States
state: Tennessee
city: El Paso
country: United States
state: Texas
city: Burlington
country: United States
state: Vermont
city: Madison
country: United States
state: Wisconsin
city: Mar del Plata
country: Argentina
state: Buenos Aires
city: Buenos Aires
country: Argentina
state: Ciudad Auton. De Buenos Aires
city: Buenos Aires
country: Argentina
state: Ciudad Auton. De Buenos Aires
city: Garran
country: Australia
state: Australian Capital Territory
city: Liverpool
country: Australia
state: New South Wales
city: Waratah
country: Australia
state: New South Wales
city: Adelaide
country: Australia
state: South Australia
city: Bendigo
country: Australia
state: Victoria
city: Frankston
country: Australia
state: Victoria
city: Perth
country: Australia
state: Western Australia
city: Linz
country: Austria
state: Oberösterreich
city: Wien
country: Austria
city: Liege
country: Belgium
state: Liège
city: Brugge
country: Belgium
city: Bruxelles - Brussel
country: Belgium
city: Edegem
country: Belgium
city: Hasselt
country: Belgium
city: Montreal
country: Canada
state: Quebec
city: Montreal
country: Canada
state: Quebec
city: Shenyang
country: China
state: Liaoning
city: Beijing
country: China
city: Beijing
country: China
city: Nanning
country: China
city: Shanghai
country: China
city: Tianjin
country: China
city: Xi'an
country: China
city: Ceske Budejovice
country: Czechia
city: Nova Ves Pod Plesi
country: Czechia
city: Nymburk
country: Czechia
city: Olomouc
country: Czechia
city: Praha 10
country: Czechia
city: Praha 2
country: Czechia
city: Praha 5
country: Czechia
city: Praha 5
country: Czechia
city: Clermont Ferrand Cedex 1
country: France
city: Lille
country: France
city: Nantes
country: France
city: Saint Cloud
country: France
city: Toulouse
country: France
city: Erlangen
country: Germany
state: Bayern
city: Frankfurt
country: Germany
state: Hessen
city: Offenbach
country: Germany
state: Hessen
city: Köln
country: Germany
state: Nordrhein-Westfalen
city: Köln
country: Germany
state: Nordrhein-Westfalen
city: Mainz
country: Germany
state: Rheinland-Pfalz
city: Stendal
country: Germany
state: Sachsen-Anhalt
city: Leipzig
country: Germany
state: Sachsen
city: Berlin
country: Germany
city: Athens
country: Greece
city: Heraklion
country: Greece
city: Ioannina
country: Greece
city: Larissa
country: Greece
city: Patras
country: Greece
city: Budapest
country: Hungary
city: Nyiregyhaza
country: Hungary
city: Pecs
country: Hungary
city: Szentes
country: Hungary
city: Szolnok
country: Hungary
city: Cork
country: Ireland
city: Dublin
country: Ireland
city: Dublin
country: Ireland
city: Dublin
country: Ireland
city: Dublin
country: Ireland
city: Galway
country: Ireland
city: Beer Sheva
country: Israel
city: Haifa
country: Israel
city: Haifa
country: Israel
city: Jerusalem
country: Israel
city: Jerusalem
country: Israel
city: Petah Tikva
country: Israel
city: Ramat Gan
country: Israel
city: Bologna
country: Italy
state: Emilia-Romagna
city: Forlì-Cesena
country: Italy
state: Emilia-Romagna
city: Modena
country: Italy
state: Emilia-Romagna
city: Ravenna
country: Italy
state: Emilia-Romagna
city: Roma
country: Italy
state: Lazio
city: Cremona
country: Italy
state: Lombardia
city: Milano
country: Italy
state: Lombardia
city: Monza-Brianza
country: Italy
state: Lombardia
city: Ancona
country: Italy
state: Marche
city: Palermo
country: Italy
state: Sicilia
city: Pisa
country: Italy
state: Toscana
city: Nagoya
country: Japan
state: Aichi
city: Matsuyama
country: Japan
state: Ehime
city: Suita
country: Japan
state: Osaka
city: Hidaka
country: Japan
state: Saitama
city: Kita-Adachigun
country: Japan
state: Saitama
city: Bunkyo
country: Japan
state: Tokyo
city: Koto-ku
country: Japan
state: Tokyo
city: Chiba
country: Japan
city: Fukuoka
country: Japan
city: Kagoshima
country: Japan
city: Osaka
country: Japan
city: Gdansk
country: Poland
city: Gdynia
country: Poland
city: Poznan
country: Poland
city: San Juan
country: Puerto Rico
city: Chelyabinsk
country: Russian Federation
city: Kazan
country: Russian Federation
city: Port Elizabeth
country: South Africa
state: Eastern Cape
city: Johannesburg
country: South Africa
state: Gauteng
city: Pretoria
country: South Africa
state: Gauteng
city: Pretoria
country: South Africa
state: Gauteng
city: Pretoria
country: South Africa
state: Gauteng
city: Santiago de Compostela
country: Spain
state: A Coruña
city: Sabadell
country: Spain
state: Barcelona
city: Terrassa
country: Spain
state: Barcelona
city: Castellón de la Plana
country: Spain
state: Castellón
city: Palma de Mallorca
country: Spain
state: Illes Baleares
city: Reus
country: Spain
state: Tarragona
city: A Coruña
country: Spain
city: Barcelona
country: Spain
city: Barcelona
country: Spain
city: Barcelona
country: Spain
city: Barcelona
country: Spain
city: Lleida
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Palma de Mallorca
country: Spain
city: Sevilla
country: Spain
city: Sevilla
country: Spain
city: Valencia
country: Spain
city: Valencia
country: Spain
city: Valencia
country: Spain
city: Stockholm
country: Sweden
city: Stockholm
country: Sweden
city: Truro
country: United Kingdom
state: Cornwall
city: Nottingham
country: United Kingdom
state: Nottinghamshire
city: London
country: United Kingdom
city: Manchester
country: United Kingdom
city: Northwood
country: United Kingdom
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
citation: Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013 Jul 22;14:228. doi: 10.1186/1745-6215-14-228.
citation: Baselga J, Zamagni C, Gomez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mangel L, Bergh J, Costa F, Gomez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roche H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.